Hemophilia may be one of the clearest examples of a win-win situation for the gene therapy field, because it's a disease with a well-characterized genetic cause, a clear marker of whether treatment is working, regulatory support for novel agents and the currently available therapies are incredibly expensive.
The Alliance for Regenerative Medicine (ARM) hosted a panel on Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?